Insider Selling: Aveanna Healthcare (NASDAQ:AVAH) Insider Sells 12,759 Shares of Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) insider Patrick Cunningham sold 12,759 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $7.65, for a total value of $97,606.35. Following the completion of the sale, the insider directly owned 374,156 shares of the company’s stock, valued at $2,862,293.40. The trade was a 3.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Aveanna Healthcare Trading Up 0.3%

Aveanna Healthcare stock traded up $0.02 during mid-day trading on Thursday, reaching $7.42. 3,877,110 shares of the company traded hands, compared to its average volume of 938,081. The company has a debt-to-equity ratio of 140.39, a current ratio of 1.23 and a quick ratio of 1.23. Aveanna Healthcare Holdings Inc. has a 52-week low of $3.67 and a 52-week high of $10.32. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of 20.61 and a beta of 2.06. The firm’s 50 day moving average price is $8.48 and its 200 day moving average price is $8.44.

Aveanna Healthcare News Summary

Here are the key news stories impacting Aveanna Healthcare this week:

• Neutral Sentiment: Short-interest data released for Feb. 19 shows an apparent data anomaly (0 shares reported / NaN change), so there’s no clear short‑interest signal to explain price moves today. (Report notes the short‑interest ratio is effectively 0 days based on reported volume.)
• Neutral Sentiment: Market commentary explains recent intraday weakness in AVAH; see a recent write‑up for context on why the stock moved. Why AVAH is Down
• Negative Sentiment: Significant insider selling: over Feb. 17–19 multiple insiders (CEO Jeff Shaner, several executives including CFO Matthew Buckhalter and CAO Deborah Stewart, plus others such as Edwin C. Reisz and Patrick A. Cunningham) sold large blocks. Combined, these filings show roughly 740,000 shares sold across the group — about $5.4–$5.5M in proceeds — at average prices in the ~$7.20–$7.65 range. Collective, high‑profile sales of this size often weigh on near‑term investor sentiment because they increase supply and may be interpreted as insiders taking money off the table. CEO Filings Other Exec Filings

Institutional Investors Weigh In On Aveanna Healthcare

Several hedge funds have recently added to or reduced their stakes in AVAH. Dynamic Technology Lab Private Ltd boosted its holdings in shares of Aveanna Healthcare by 8.9% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 14,149 shares of the company’s stock valued at $126,000 after acquiring an additional 1,151 shares during the last quarter. Barclays PLC raised its holdings in shares of Aveanna Healthcare by 0.8% during the third quarter. Barclays PLC now owns 179,359 shares of the company’s stock valued at $1,591,000 after purchasing an additional 1,366 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Aveanna Healthcare by 4.5% during the third quarter. Franklin Resources Inc. now owns 35,630 shares of the company’s stock valued at $316,000 after purchasing an additional 1,528 shares during the last quarter. Intech Investment Management LLC lifted its position in Aveanna Healthcare by 9.8% during the fourth quarter. Intech Investment Management LLC now owns 19,483 shares of the company’s stock valued at $159,000 after purchasing an additional 1,739 shares during the period. Finally, Balboa Wealth Partners boosted its holdings in Aveanna Healthcare by 13.5% in the fourth quarter. Balboa Wealth Partners now owns 16,890 shares of the company’s stock worth $138,000 after purchasing an additional 2,007 shares during the last quarter. 87.96% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

AVAH has been the subject of several research analyst reports. Truist Financial raised their price objective on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “hold” rating in a report on Friday, November 7th. UBS Group increased their target price on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “neutral” rating in a research report on Thursday, January 15th. Royal Bank Of Canada lifted their price target on Aveanna Healthcare from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Thursday, January 15th. Zacks Research cut Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $11.06.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.